Dr. Silvia Pagoada Vallecillo, MD

Dr. Pagoada Vallecillo practices at Poplar Bluff Regional Medical Center in Poplar Bluff, Missouri, part of Community Health Systems.

Dr. Pagoada Vallecillo's NPI, 1144624982, was assigned on October 21, 2014. Dr. Pagoada Vallecillo holds Missouri license 2018023741.

Dr. Pagoada Vallecillo's primary practice is Poplar Bluff Regional Medical Center, at 3100 Oak Grove Road, Poplar Bluff, MO 63901 in Butler County. The practice phone is (573) 785-7721.

Dr. Pagoada Vallecillo's primary practice is Poplar Bluff Regional Medical Center in Poplar Bluff, Missouri, part of Community Health Systems. The medical group on file is Poplar Bluff Regional Medical Center. Dmand AI also links Dr. Pagoada Vallecillo to 2 more medical groups and 1 community health center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pagoada Vallecillo practices, 2 sites in all. Vendor and product names are available with a free account.

Family medicine is Dr. Pagoada Vallecillo's primary specialty in the NPI Registry, under taxonomy code 207Q00000X. Dr. Pagoada Vallecillo is licensed in Missouri.

CMS data shows 641 Medicare services from Dr. Pagoada Vallecillo across 7 procedure codes in 2024, for 174 Medicare patients. Medicare paid $55,042 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 174 Medicare patients who saw Dr. Pagoada Vallecillo in 2024. The largest group is 65 to 74, with 57 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 43% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pagoada Vallecillo's median patient age at 75, with 54% women.

In 2024, Dr. Pagoada Vallecillo wrote 332 Medicare Part D claims for 115 patients. 93% of them were for generic drugs. CMS names the drug for 192 of them, across 10 drugs with 11 or more claims each, at $964 in total drug cost. In 2023, CMS named 37 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 50 out of 100 for Dr. Pagoada Vallecillo for performance year 2024, reported as part of a group. Dr. Pagoada Vallecillo accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 15 general payments to Dr. Pagoada Vallecillo from 6 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $728.